Dasatinib Clinical Trials
25 recruitingDrug
Phase 219Phase 14Phase 32Early Phase 12Phase 41
Showing 1–20 of 25 trials
Recruiting
Phase 2
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
B Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)222 enrolled141 locationsNCT06124157
Recruiting
Phase 2
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Advanced Solid TumorsMultiple MyelomaLymphoma, Non-Hodgkin
Canadian Cancer Trials Group720 enrolled10 locationsNCT03297606
Recruiting
Phase 3
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
National Cancer Institute (NCI)348 enrolled211 locationsNCT04530565
Recruiting
Phase 2
Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE
Acute Myeloid Leukemia
Institut Paoli-Calmettes35 enrolled1 locationNCT06055621
Recruiting
Phase 4
Asciminib Roll-over Study
Chronic Myelogenous LeukemiaLeukemia, Myelogenous, Chronic, BCR-ABL Positive
Novartis Pharmaceuticals347 enrolled84 locationsNCT04877522
Recruiting
Phase 2
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
T-cell LymphomaT-cell Acute Lymphoblastic LeukemiaMixed Phenotype Acute Leukemia
St. Jude Children's Research Hospital100 enrolled3 locationsNCT06390319
Recruiting
Phase 2
Improving Physical Ability and Cellular Senescence Elimination in HIV
FrailtyHIVAging Problems+1 more
National Institute of Allergy and Infectious Diseases (NIAID)80 enrolled27 locationsNCT07144293
Recruiting
Phase 2
ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase
Philadelphia Chromosome PositiveChronic Phase Chronic Myelogenous LeukemiaBCR-ABL1 Positive Chronic Myelogenous Leukemia+1 more
M.D. Anderson Cancer Center70 enrolled1 locationNCT05007873
Recruiting
Phase 2
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma
St. Jude Children's Research Hospital128 enrolled2 locationsNCT06533748
Recruiting
Phase 1
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
Mixed Phenotype Acute LeukemiaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1B Acute Lymphoblastic Leukemia+2 more
OHSU Knight Cancer Institute20 enrolled1 locationNCT04872790
Recruiting
Phase 2
Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Refractory Multiple MyelomaRecurrent Multiple Myeloma
Mayo Clinic44 enrolled1 locationNCT06940297
Recruiting
Early Phase 1
Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease
Glioma
Mayo Clinic10 enrolled1 locationNCT07025226
Recruiting
Phase 2
Fortifying Healthy Behaviors, Optimizing Medical Therapies and Enhancing Cognitive Function in Older Adults-pilot Study
Older AdultsCognitive DeclineAging+1 more
Washington University School of Medicine20 enrolled1 locationNCT07000734
Recruiting
Phase 1
ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
B-cell Acute Lymphoblastic LeukemiaChronic Myeloid Leukemia (CML) in Lymphoid Blast CrisisPhiladelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL
Marlise Luskin, MD40 enrolled4 locationsNCT03595917
Recruiting
Phase 1Phase 2
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent+2 more
Princess Maxima Center for Pediatric Oncology26 enrolled33 locationsNCT05751044
Recruiting
Phase 2Phase 3
Newly-diagnosed Pediatric T-cell ALL Protocol
Acute Lymphoblastic LeukemiaChildhood Leukemia, Acute LymphoblasticT Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Institute of Hematology & Blood Diseases Hospital, China610 enrolled27 locationsNCT06855810
Recruiting
Phase 2
Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Chronic Phase Chronic Myelogenous Leukemia
Medical College of Wisconsin51 enrolled4 locationsNCT04838041
Recruiting
Phase 2
Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction
Metastatic Prostate Cancer
St Vincent's Hospital, Sydney22 enrolled2 locationsNCT04925648
Recruiting
Phase 2
Safety, Tolerance and Antiretroviral Activity of Dasatinib: a Pilot Clinical Trial in Patients With Recent HIV-1 Infection
Recent HIV-1 Infection
Eva Bonfill24 enrolled1 locationNCT05527418
Recruiting
Early Phase 1
Pilot Trial for Treatment of Recurrent Glioblastoma
GlioblastomaRecurrent GlioblastomaRecurrent Disease
AHS Cancer Control Alberta10 enrolled1 locationNCT05432518